Preservation of Ovaries in Endometrial Cancer: GYN POEM Trial

Summary: To examine the decision-making process of patients who choose to undergo or not undergo ovarian-sparing surgical treatment of endometrial cancer to identify influencing factors - in particular, cancer-related psychological distress and reproductive concerns - and any potential decisional regrets following surgical intervention.

Sponsor(s): MSK

Detail: The purpose of this study is to learn how cancer-related distress and/or reproductive concerns affect a woman's decision to remove or preserve her ovaries during surgery for endometrial cancer. Participants in this study will include premenopausal woman with endometrial cancer who will be having surgery to treat the cancer. Before the surgery, they will decide whether to preserve their ovaries or have them removed. Preserving the ovaries will allow them to harvest their eggs after surgery and help manage their hormone levels.

Researchers will also assess ovarian reserve in participants who choose to preserve their ovaries. All participants will be monitored for recurrence of cancer after surgery according to the standard of care, including physical examinations, biopsy procedures (if needed), and imaging scans (if needed).

Criteria:
Key Inclusion Criteria:

  1. Women aged ≥18 and ≤50 years
  2. Premenopausal
  3. Endometrioid histological diagnosis
  4. Scheduled for surgical intervention
  5. FIGO grade 1-2, clinical stage I
  6. Disease confined to uterus, no clear evidence of deep (≥50%) myoinvasion on imaging (MRI preferred, ultrasound optional)
  7. Normal ovaries on preoperative imaging

Exclusion Criteria:

  1. Known Lynch syndrome
  2. Prior bilateral oophorectomy
  3. Personal history of hormone receptor-positive breast carcinoma
  4. Increased risk of ovarian cancer identified on the basis of family or personal history
  5. Women currently on hormonal contraception, letrozole, or tamoxifen may not opt-in to AMH
  6. Women who recently underwent ovarian stimulation within the past 3 months may not opt-in to AMH
  7. Women who have pituitary dysfunction (or any pituitary disorders) may not opt-in to AMH
  8. Women who completed chemotherapy within <12 months may not opt-in to AMH

Location(s): Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut and MidState Medical Center

Contact(s): Becca Gripp 860-972-5371 rebecca.gripp@hhchealth.org and Siobhan Reilly 860-696-4958 siobhan.reilly@hhchealth.org

MSK_ClinicalTrials_Ad